| Today, Tue, Dec 22, 2009 | | • | Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals
PR Newswire (Tue 1:30am)
| | Mon, Dec 21, 2009 | | • | UPDATE - CTI says cancer drug gets orphan status in Europe
at Reuters (Mon 7:20am)
| | • | European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
PR Newswire (Mon 1:30am)
| | Fri, Dec 18, 2009 | | • | CELL THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Fri, Dec 18)
| | • | Biotech Stock Mailbag: Year in Review
at TheStreet.com (Fri, Dec 18)
| | Thu, Dec 17, 2009 | | • | CELL THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibi
EDGAR Online (Thu, Dec 17)
| | • | Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
PR Newswire (Thu, Dec 17)
| | Wed, Dec 16, 2009 | | • | 3 Reasons You Should Ignore Everyone's Predictions for 2010
at Motley Fool (Wed, Dec 16)
| | • | Cell Therapeutics Gets FDA Panel for Lymphoma Drug: BioBuzz
at TheStreet.com (Wed, Dec 16)
| | Tue, Dec 15, 2009 | | • | Biotech Calendar: Upcoming FDA Dates
at TheStreet.com (Tue, Dec 15)
| | Fri, Dec 11, 2009 | | • | Biotech Stock Mailbag: Cell Therapeutics
at TheStreet.com (Fri, Dec 11)
| | • | Stock Watch: Beacon Equity Issues Market Alert for Cell Therapeutics Inc.
GlobeNewswire (Fri, Dec 11)
| | Wed, Dec 9, 2009 | | • | A Strategy for All Situations
at Motley Fool (Wed, Dec 9)
| | • | Cell Therapeutics' Positive Data
Zacks.com (Wed, Dec 9)
| | Tue, Dec 8, 2009 | | • | Cell Therapeutics on Dilution Watch: BioBuzz
at TheStreet.com (Tue, Dec 8)
| | • | Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
PR Newswire (Tue, Dec 8)
| | Mon, Dec 7, 2009 | | • | Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
PR Newswire (Mon, Dec 7)
| | Wed, Dec 2, 2009 | | • | New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
PR Newswire (Wed, Dec 2)
| | Tue, Dec 1, 2009 | | • | Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
PR Newswire (Tue, Dec 1)
| | Mon, Nov 30, 2009 | | • | CELL THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi
EDGAR Online (Mon, Nov 30)
|
Add CTIC News to My Yahoo!:
 
| |
|
0.49% Nasdaq 
0.038 (3.22%) 
Headlines
